118 related articles for article (PubMed ID: 1711131)
1. [Prediction of remission in Graves' disease after thionamide therapy by technetium-99m early uptake].
Misaki T; Dokoh S; Koh T; Shimbo S; Hidaka A; Iida Y; Kasagi K; Konishi J
Kaku Igaku; 1991 Feb; 28(2):157-61. PubMed ID: 1711131
[TBL] [Abstract][Full Text] [Related]
2. High pre-therapy [99mTc]pertechnetate thyroid uptake, thyroid size and thyrostatic drugs: predictive factors of failure in [131I]iodide therapy in Graves' disease.
Zantut-Wittmann DE; Ramos CD; Santos AO; Lima MM; Panzan AD; Facuri FV; Etchebehere EC; Lima MC; Tambascia MA; Camargo EE
Nucl Med Commun; 2005 Nov; 26(11):957-63. PubMed ID: 16208172
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the factors associated with Tc-99m pertechnetate uptake in thyrotoxicosis and graves' disease.
Kidokoro-Kunii Y; Emoto N; Cho K; Oikawa S
J Nippon Med Sch; 2006 Feb; 73(1):10-7. PubMed ID: 16538017
[TBL] [Abstract][Full Text] [Related]
4. Prediction of remission in Graves' disease treated with long-term carbimazole therapy: evaluation of technetium-99m thyroid uptake and TSH concentrations as prognostic indicators.
Prakash R
Eur J Nucl Med; 1996 Feb; 23(2):118-22. PubMed ID: 8925844
[TBL] [Abstract][Full Text] [Related]
5. Scintigraphic findings of the thyroid in euthyroid ophthalmic Graves' disease.
Kasagi K; Hidaka A; Misaki T; Miyamoto S; Takeuchi R; Sakahara H; Sasayama S; Iida Y; Konishi J
J Nucl Med; 1994 May; 35(5):811-7. PubMed ID: 8176463
[TBL] [Abstract][Full Text] [Related]
6. Practical treatment with minimum maintenance dose of anti-thyroid drugs for prediction of remission in Graves' disease.
Kashiwai T; Hidaka Y; Takano T; Tatsumi KI; Izumi Y; Shimaoka Y; Tada H; Takeoka K; Amino N
Endocr J; 2003 Feb; 50(1):45-9. PubMed ID: 12733708
[TBL] [Abstract][Full Text] [Related]
7. Thyrotoxic Graves' disease with normal thyroidal technetium-99m pertechnetate uptake.
Ikekubo K; Hino M; Ito H; Koh T; Ishihara T; Kurahachi H; Kasagi K; Hidaka A; Mori T
Ann Nucl Med; 1990 Jul; 4(2):43-8. PubMed ID: 2171608
[TBL] [Abstract][Full Text] [Related]
8. Effects of chronic iodine administration on thyroid status in euthyroid subjects previously treated with antithyroid drugs for Graves' hyperthyroidism.
Roti E; Gardini E; Minelli R; Bianconi L; Salvi M; Gavaruzzi G; Braverman LE
J Clin Endocrinol Metab; 1993 Apr; 76(4):928-32. PubMed ID: 7682562
[TBL] [Abstract][Full Text] [Related]
9. PREDICTION OF RELAPSE FROM HYPERTHYROIDISM FOLLOWING ANTITHYROID MEDICATION WITHDRAWAL USING TECHNETIUM THYROID UPTAKE SCANNING.
Nakhjavani M; Abdollahi S; Farzanefar S; Abousaidi M; Esteghamati A; Naseri M; Eftekhari M; Abbasi M
Endocr Pract; 2017 Apr; 23(4):466-470. PubMed ID: 28437154
[TBL] [Abstract][Full Text] [Related]
10. Cutoff value of thyroid uptake of (99m)Tc-pertechnetate to discriminate between Graves' disease and painless thyroiditis: a single center retrospective study.
Uchida T; Suzuki R; Kasai T; Onose H; Komiya K; Goto H; Takeno K; Ishii S; Sato J; Honda A; Kawano Y; Himuro M; Yamada E; Yamada T; Watada H
Endocr J; 2016; 63(2):143-9. PubMed ID: 26581846
[TBL] [Abstract][Full Text] [Related]
11. Studies on the T3 suppression test by the 24-hour thyroidal 131I uptake in patients with Graves' disease: comparison of the effects of propylthiouracil and methylmercaptoimidazole.
Kobayashi I; Maruta S; Mori M; Ishii H; Ishihara H; Iriuchijima T; Takahashi M; Shimomura Y; Fukuda H
Endocrinol Jpn; 1983 Aug; 30(4):491-7. PubMed ID: 6200318
[TBL] [Abstract][Full Text] [Related]
12. Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves' hyperthyroidism.
Romaldini JH; Bromberg N; Werner RS; Tanaka LM; Rodrigues HF; Werner MC; Farah CS; Reis LC
J Clin Endocrinol Metab; 1983 Sep; 57(3):563-70. PubMed ID: 6192139
[TBL] [Abstract][Full Text] [Related]
13. [The prognosis of Graves' disease after antithyroid drug treatment: clinical significance of the T3 suppression test and abnormal thyroid stimulators].
Iida Y; Konishi J; Kasagi K; Misaki T; Endo K; Nesumi N; Torizuka K; Tanaka K; Ishii H; Naito K; Nishikawa M; Inada M; Imura H; Kuma K
Nihon Naibunpi Gakkai Zasshi; 1982 Jun; 58(6):796-806. PubMed ID: 6180937
[TBL] [Abstract][Full Text] [Related]
14. Pituitary-thyroid regulation in euthyroid patients with Graves' disease previously treated with antithyroid drugs.
Buerklin EM; Schimmel M; Utiger RD
J Clin Endocrinol Metab; 1976 Aug; 43(2):419-27. PubMed ID: 59733
[TBL] [Abstract][Full Text] [Related]
15. Remission of Graves' disease is not related to early restoration of euthyroidism with high-dose methimazole therapy.
Kruljac I; Solter D; Vrkljan AM; Solter M
Endocr Res; 2015; 40(1):25-8. PubMed ID: 24833206
[TBL] [Abstract][Full Text] [Related]
16. Thyroid blood flow and uptake of technetium-99m pertechnetate in Graves' disease.
Sekulić V; Rajić M; Vlajković M; Ilić S; Bogićević M; Antić S; Dimić D
Hell J Nucl Med; 2006; 9(3):173-6. PubMed ID: 17160158
[TBL] [Abstract][Full Text] [Related]
17. Remission of Graves' disease during anti-thyroid drug therapy. Time to reconsider the mechanism?
Laurberg P
Eur J Endocrinol; 2006 Dec; 155(6):783-6. PubMed ID: 17132745
[TBL] [Abstract][Full Text] [Related]
18. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients.
Chung YJ; Lee BW; Kim JY; Jung JH; Min YK; Lee MS; Lee MK; Kim KW; Chung JH
Thyroid; 2006 Dec; 16(12):1251-7. PubMed ID: 17199435
[TBL] [Abstract][Full Text] [Related]
19. Technetium thyroid uptake ratios in pediatric Graves disease.
Duck SC; Sty J
J Pediatr; 1985 Dec; 107(6):905-9. PubMed ID: 2999367
[TBL] [Abstract][Full Text] [Related]
20. Novel Application of Quantitative Single-Photon Emission Computed Tomography/Computed Tomography to Predict Early Response to Methimazole in Graves' Disease.
Kim HJ; Bang JI; Kim JY; Moon JH; So Y; Lee WW
Korean J Radiol; 2017; 18(3):543-550. PubMed ID: 28458607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
